Baroreflex sensitivity and central hemodynamics after omega-3 polyunsaturated fatty acids supplementation in an animal model of menopause

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 65-69

  Losurdo, Pasquale ^a   Grillo, Andrea ^a   Panizon, Emiliano ^a   Zanetti, Michela ^a   Bardelli, Moreno ^a   Biolo, Gianni ^a   Fabris, Bruno ^a   Carretta, Renzo ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Arterial stiffness; Baroreflex; Cardiovascular disease; Menopause; Omega 3 polyunsaturated fatty acids; Ovariectomized rats

Indexed keywords

OMEGA 3 FATTY ACID; PHENYLEPHRINE;

ANIMAL EXPERIMENT; AORTA PRESSURE; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; ARTICLE; BAROREFLEX SENSITIVITY; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMODYNAMICS; MENOPAUSE; NONHUMAN; OVARIECTOMY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION; WISTAR RAT; ANIMAL; ANIMAL MODEL; DIETARY SUPPLEMENT; DRUG EFFECTS; METABOLISM; PHYSIOLOGY;

ANIMALS; BAROREFLEX; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HEMODYNAMICS; MENOPAUSE; MODELS, ANIMAL; OVARIECTOMY; RATS; RATS, WISTAR;

EID: 84937977852     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2014.12.005     Document Type: Article

References (47)

1. World Health Organization The top 10 causes of death [Accessed 8 March 2014]. http://who.int/mediacentre/factsheets/fs310/en/.
2. Berlin J.A., Ellenberg S.S. Inclusion of women in clinical trials. BMC Med 2009, 7(1):56.
3. Sardar M.R., Badri M., Prince C.T., Seltzer J., Kowey P.R. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med. 2014, 174(11):1868-1870.
4. Kim A.M., Tingen C.M., Woodruff T.K. Sex bias in trials and treatment must end. Nature 2010, 465(7299):688-689.
5. Zucker I., Beery A.K. Males still dominate animal studies. Nature 2010, 465(7299):690.
6. Kannel W.B., Wilson P.W. Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 1995, 155:57-61.
7. Xing D., Nozell S., Chen Y.F., Hage F., Oparil S. Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol 2009, 29:289-295.
8. Flues K., Paulini J., Brito S. Exercise training associated with estrogen therapy induced cardiovascular benefits after ovarian hormones deprivation. Maturitas 2010, 65:267-271.
9. Morey A.K., Pedram A., Razandi M. Estrogen and progesterone inhibit vascular smooth muscle proliferation. Endocrinology 1997, 138:3330-3339.
10. Wassmann S., Bäumer A.T., Strehlow K. Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats. Circulation 2001, 103:435-441.
11. Zaydun G., Tomiyama H., Hashimoto H. Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase. Atherosclerosis 2006, 184:137-142.
12. Bechlioulis A., Kalantaridou S.N., Naka K.K. Endothelial function, but not carotid intima-media thickness, is affected early in menopause and is associated with severity of hot flushes. J Clin Endocrinol Metab 2010, 95:1199-1206.
13. Huikuri H.V., Pikkujämsä S.M., Airaksinen K.E. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 1996, 94:122-125.
14. Kleiger R.E., Miller J.P., Bigger J.T., Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987, 59:256-262.
15. La Rovere M.T., Bigger J.T., Marcus F.I., Mortara A., Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998, 351:478-484.
16. Rizos E.C., Elisaf M.S. Current evidence and future perspectives of omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease. Eur J Pharmacol 2013, 706:1-3.
17. Pase M.P., Grima N.A., Sarris J. Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. Br J Nutr 2011, 106:974-980.
18. Billman G.E. Effect of dietary omega-3 polyunsaturated fatty acids on heart rate and heart rate variability in animals susceptible or resistant to ventricular fibrillation. Front Physiol 2012, 3:71.
19. Losurdo P., Grillo A., Panizon E. Supplementation of omega-3 polyunsaturated fatty acids prevents increase in arterial stiffness after experimental menopause. J Cardiovasc Pharmacol Ther 2014, 19:114-120.
20. Gortan Cappellari G., Losurdo P., Mazzucco S. Treatment with n-3 polyunsaturated fatty acids reverses endothelial dysfunction and oxidative stress in experimental menopause. J Nutr Biochem 2013, 24:371-379.
21. Yanes L.L., Reckelhoff J.F. Postmenopausal hypertension. Am J Hypertens 2011, 24:740-749.
22. Lungershausen Y.K., Abbey M., Nestel P., Howe P. Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J Hypertens 1994, 12:1041-1046.
23. Rutai H., St Louis J., Falardeau P. Antihypertensive properties of linoleic acid and fish oil omega-3 fatty acids independent of the prostaglandin system. Am J Hypertens 1989, 2:610-617.
24. Mozaffarian D., Wu J.H. Omega-3 fatty acids and cardiovascular disease effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 2011, 58:2047-2067.
25. He X.R., Wang W., Crofton J.T., Share L. Effects of 17beta-estradiol on sympathetic activity and pressor response to phenylephrine in ovariectomized rats. Am J Physiol 1998, 275:1202-1208.
26. Pamidimukkala J., Taylor J.A., Welshons W.V., Lubahn D.B., Hay M. Estrogen modulation of baroreflex function in conscious mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:983-989.
27. Goldman R.K., Azar A.S., Mulvaney J.M., Hinojosa-Laborde C., Haywood J.R., Brooks V.L. Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids. Am J Physiol Regul Integr Comp Physiol 2009, 296:1419-1426.
28. Kikuya M., Hozawa A., Ohkubo T. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000, 36:901-906.
29. Geleijnse J.M., Giltay E.J., Grobbee D.E., Donders A.R., Kok F.J. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002, 20:1493-1499.
30. Andresen M.C. Short-and long-term determinants of baroreceptor function in aged normotensive and spontaneously hypertensive rats. Circ Res 1984, 54:750-759.
31. Chapleau M.W., Cunningham J.T., Sullivan M.J., Wachtel R.E., Abboud F.M. Structural versus functional modulation of the arterial baroreflex. Hypertension 1995, 26:341-347.
32. Okada Y., Galbreath M.M., Shibata S. Relationship between sympathetic baroreflex sensitivity and arterial stiffness in elderly men and women. Hypertension 2012, 59:98-104.
33. Buckberg G.D., Fixler D.E., Archie J.P., Hoffman J.I. Experimental subendocardial ischemia in dog with normal coronary arteries. Circ Res 1972, 30:67-81.
34. Tsiachris D., Tsioufis C., Syrseloudis D. Subendocardial viability ratio as an index of impaired coronary flow reserve in hypertensives without significant coronary artery stenoses. J Hum Hypertens 2011, 26:64-70.
35. Guelen I., Mattace-Raso F.U., van Popele N.M. Aortic stiffness and the balance between cardiac oxygen supply and demand: the Rotterdam Study. Hypertension 2008, 26:1237-1243.
36. Salvi P. Pulse waves: how vascular hemodynamics affects blood pressure 2012, Springer.
37. McVeigh G.E., Allen P.B., Morgan D.R., Hanratty C.G., Silke B. Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci (Lond) 2001, 100:387-393.
38. Karlen-Amarante M., da Cunha N.V., de Andrade O., de Souza H.C.D., Martins-Pinge M.C. Altered baroreflex and autonomic modulation in monosodium glutamate-induced hyperadipose rats. Metabolism 2012, 61(10):1435-1442.
39. Guimaraes P.S., Huber D.A., Campagnole-Santos M.J., Schreihofer A.M. Development of attenuated baroreflexes in obese Zucker rats coincides with impaired activation of nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol 2014, 306(9):R681-R692.
40. Witt P.M., Christensen J.H., Ewertz M., Aardestrup I.V., Schmidt E.B. The incorporation of marine n-3 PUFA into platelets and adipose tissue in pre-and postmenopausal women: a randomised, double-blind, placebo-controlled trial. Br J Nutr 2010, 104:318-325.
41. Hunt W., McManus A. Women's health care: the potential of long-chain omega-3 polyunsaturated fatty acids. J Women Health Care 2014, 3:2167-0420.
42. Bosch J., Gerstein H.C., Dagenais G.R., Díaz R., Dyal L., Jung H., et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012, 367(4):309-318.
43. Roncaglioni M.C., Tombesi M., Avanzini F., Barlera S., Caimi V., Longoni P., et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013, 368(19):1800-1808.
44. Galan P., Kesse-Guyot E., Czernichow S., Briancon S., Blacher J., Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010, 341.
45. Kromhout D., Giltay E.J., Geleijnse J.M. n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010, 363(21):2015-2026.
46. Rauch B., Schiele R., Schneider S., Diller F., Victor N., Gohlke H., et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010, 122(21):2152-2159.
47. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372(9645):1223-1230.